Table 2.

Multivariate analysis of factors associated with PFS at PRRT2

Variables	Categories	No. of patients	No. of patients progressed	Median PFS (months)	Median PFS 95% CI	p-value
Sex	F	22	19	19.7	(11.8–32.7)
M	21	18	14.7	6.4-not reached	0.012
Grade of tumour	G1	13	11	20.7	11.1-not reached
G2	16	14	13.2	8.9- not reached	0.053
G3	4	3	15.3	3.8- not reached	0.841
Site of primary NET	Midgut	20	19	17.2	(6.4–27.5)
Pancreas	13	11	20.3	14.7-not reached	0.154
Hindgut	2	1	6.7	6.7-not reached	0.355
Other	8	6	10.8	6.8-not reached	0.625
Percentage liver lesions	No metastases	5	3	12.8	8.9-not reached
0–25% metastases	12	10	21.4	14.7-not reached	0.031
25–50% metastases	18	17	17.2	(5.5–32.7)	0.041
>50% metastases	6	6	12.1	2.1-not reached	0.007
PFS post-PRRT1	PFS < 30 months	21	19	12.8	(6.8–21.2)
PFS > 30 months	20	17	22.9	(18.7–32.7)	0.073
Age	<55	23	20	17.5	(11.8–23.8)
55+	20	17	18.4	6.7-not reached	0.123

CI, confidence interval; NET, neuroendocrine tumour; PFS, progression-free survival; PRRT, peptide receptor radionuclide therapy.